BR112022003648A2 - Iniciadores e construto de t car complexo de maturação de célula-b - Google Patents

Iniciadores e construto de t car complexo de maturação de célula-b

Info

Publication number
BR112022003648A2
BR112022003648A2 BR112022003648A BR112022003648A BR112022003648A2 BR 112022003648 A2 BR112022003648 A2 BR 112022003648A2 BR 112022003648 A BR112022003648 A BR 112022003648A BR 112022003648 A BR112022003648 A BR 112022003648A BR 112022003648 A2 BR112022003648 A2 BR 112022003648A2
Authority
BR
Brazil
Prior art keywords
car
primers
cell maturation
complex
construct
Prior art date
Application number
BR112022003648A
Other languages
English (en)
Inventor
Dee Shen
Rebecca George
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112022003648A2 publication Critical patent/BR112022003648A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

iniciadores e construto de t car complexo de maturação de célula-b. a presente invenção fornece conjuntos de sonda e iniciadores, e métodos e kits relacionados, para gerar células t com receptor de antígeno quimérico (car) antígeno de maturação de célula-b. a invenção também fornece conjuntos de sonda e iniciadores, e métodos e kits relacionados, para realizar reações em cadeia da polimerase quantitativas para quantificar a integração de transgene de car antígeno de maturação de célula-b em um produto de fármaco de t car.
BR112022003648A 2019-08-30 2020-08-28 Iniciadores e construto de t car complexo de maturação de célula-b BR112022003648A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894663P 2019-08-30 2019-08-30
PCT/IB2020/058070 WO2021038524A1 (en) 2019-08-30 2020-08-28 B-cell maturation complex car t construct and primers

Publications (1)

Publication Number Publication Date
BR112022003648A2 true BR112022003648A2 (pt) 2022-05-24

Family

ID=72356220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003648A BR112022003648A2 (pt) 2019-08-30 2020-08-28 Iniciadores e construto de t car complexo de maturação de célula-b

Country Status (12)

Country Link
US (1) US20210164045A1 (pt)
EP (1) EP4022091A1 (pt)
JP (1) JP2022546978A (pt)
KR (1) KR20220051002A (pt)
CN (1) CN114341365A (pt)
AU (1) AU2020339086A1 (pt)
BR (1) BR112022003648A2 (pt)
CA (1) CA3152237A1 (pt)
IL (1) IL290926A (pt)
JO (1) JOP20220049A1 (pt)
MX (1) MX2022002466A (pt)
WO (1) WO2021038524A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210332448A1 (en) * 2020-03-09 2021-10-28 Janssen Pharmaceutica Nv Compositions and methods for quantifying integration of recombinant vector nucleic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909099B1 (fr) * 2006-11-24 2012-10-19 Univ Aix Marseille Ii Methode de diagnostic et de suivi d'une vaginose bacterienne par quantification moleculaire.
US20110251091A1 (en) * 2008-09-12 2011-10-13 Cornell University Thyroid tumors identified
CA2984484C (en) * 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
US10968426B2 (en) * 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
CN109971836A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 双重荧光定量pcr测定car拷贝数的方法和试剂盒
CN109722468A (zh) * 2019-02-28 2019-05-07 上海邦耀生物科技有限公司 检测bcma嵌合抗原受体基因的pcr引物组合及应用
CN109722472A (zh) * 2019-02-28 2019-05-07 上海邦耀生物科技有限公司 检测嵌合抗原受体基因的通用型pcr引物组合及应用

Also Published As

Publication number Publication date
JOP20220049A1 (ar) 2023-01-30
CA3152237A1 (en) 2021-03-04
KR20220051002A (ko) 2022-04-25
IL290926A (en) 2022-04-01
AU2020339086A1 (en) 2022-04-14
WO2021038524A1 (en) 2021-03-04
US20210164045A1 (en) 2021-06-03
MX2022002466A (es) 2022-06-02
JP2022546978A (ja) 2022-11-10
CN114341365A (zh) 2022-04-12
EP4022091A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
UY38546A (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
BR112022008522A2 (pt) Usos de receptores de antígeno quimérico anti-bcma
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
BR112017021500A2 (pt) terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
BR112019017120A8 (pt) Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
MX2020004243A (es) Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
BR112016029372A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico isolado, vetor, métodos para produzir um anticorpo isolado ou fragmento de ligação de antígeno do mesmo, para preparar um conjugado e para aliviar um sintoma de um câncer, conjugado, e, uso de um conjugado.
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
PE20141017A1 (es) Anticuerpos del cea
AR088883A1 (es) Moleculas de union para bcma y cd3
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS